Abstract:Abstract The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees. Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture. The risks of HT differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used. Treatment should be individualized to identify the most appropriate HT type, dose, formulation, route of administration, and duration of use, using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing or discontinuing HT. For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is most favorable for treatment of bothersome VMS and for those at elevated risk for bone loss or fracture. For women who initiate HT more than 10 or 20 years from menopause onset or are aged 60 years or older, the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. Longer durations of therapy should be for documented indications such as persistent VMS or bone loss, with shared decision making and periodic reevaluation. For bothersome GSM symptoms not relieved with over-the-counter therapies and without indications for use of systemic HT, low-dose vaginal estrogen therapy or other therapies are recommended. This NAMS position statement has been endorsed by Academy of Women's Health, American Association of Clinical Endocrinologists, American Association of Nurse Practitioners, American Medical Women's Association, American Society for Reproductive Medicine, Asociación Mexicana para el Estudio del Climaterio, Association of Reproductive Health Professionals, Australasian Menopause Society, Chinese Menopause Society, Colegio Mexicano de Especialistas en Ginecologia y Obstetricia, Czech Menopause and Andropause Society, Dominican Menopause Society, European Menopause and Andropause Society, German Menopause Society, Groupe d’études de la ménopause et du vieillissement Hormonal, HealthyWomen, Indian Menopause Society, International Menopause Society, International Osteoporosis Foundation, International Society for the Study of Women's Sexual Health, Israeli Menopause Society, Japan Society of Menopause and Women's Health, Korean Society of Menopause, Menopause Research Society of Singapore, National Association of Nurse Practitioners in Women's Health, SOBRAC and FEBRASGO, SIGMA Canadian Menopause Society, Società Italiana della Menopausa, Society of Obstetricians and Gynaecologists of Canada, South African Menopause Society, Taiwanese Menopause Society, and the Thai Menopause Society. The American College of Obstetricians and Gynecologists supports the value of this clinical document as an educational tool, June 2017. The British Menopause Society supports this Position Statement.

Society for Maternal-Fetal Medicine Position Statement: Access to abortion care

Society for Maternal-Fetal Medicine Position Statement: Paid family and medical leave

What role should maternal-fetal medicine physicians play in the era of abortion restriction?

The IAPM New York 2024 declaration on professional responsibility and abortion

A tale of two societies: implications of conflicting Rh-immunoglobulin guidelines

The Association of Federal Medicaid Abortion Funding Restrictions With Adverse Obstetric Outcomes Among United States Medicaid Recipients

The importance of professional responsibility and fetal viability in the management of abortion

Brief of over 300 reproductive health researchers as Amici Curiae in FDA v. Alliance for Hippocratic Medicine

Maternal-fetal surgery for myelomeningocele: some thoughts on ethical, legal, and psychological issues in a Western European situation

The Rights of Physicians and Future Physicians Who Are Lactating, Breastfeeding, or Chestfeeding: An American Medical Women’s Association Position Article

The 2017 hormone therapy position statement of The North American Menopause Society

Abortion as Essential Health Care and the Critical Role Your Practice Can Play in Protecting Abortion Access

Corrigendum: The impact of hostile abortion legislation on the United States maternal mortality crisis: a call for increased abortion education

Contraception and Abortion

Society of NeuroInterventional Surgery: position statement on pregnancy and parental leave for physicians practicing neurointerventional surgery

Professional societies of obstetrics and gynecology as agents of change in sexual and reproductive health: FIGO 's 10‐country safe abortion advocacy project in Africa and Latin America

Navigating the Impact of the Dobbs Decision: Perspectives from Pediatric Surgeons on Reproductive Health Care

FIGO and ICM joint statement on contraception: 2024

Increasing Access to Medications and Devices for the Care of Low-Risk Childbearing Families: An Analysis of Existing Law and Strategies for Advocacy

EUROPEAN ASSOCIATION OF PERINATAL MEDICINE (EAPM) EUROPEAN BOARD AND COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS (EBCOG) EUROPEAN MIDWIVES ASSOCIATION (EMA). Joint position statement: substandard and disrespectful care in labour – because words matter

Amicus brief of over 300 reproductive health researchers supports mifepristone's safety and effectiveness